Ignis Therapeutics (Suzhou) Co. Ltd. has patented new muscarinic M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of schizophrenia, bipolar disorder, Huntington’s, Alzheimer’s, inflammatory bowel disease, drug-induced dyskinesia, pain and skin lesions.